Funders such as the NIH and NCI are promoting multidisciplinary research for identifying medical discoveries that may lead to a healthier USA. Funded by the NIH, a nutritionist, neonatologist, and I are co-leading a multidisciplinary Bayesian adaptive clinical trial supporting the assessment of docosahexaenoic acid (DHA) on reducing early preterm birth (ADORE). This Bayesian adaptive trial design was supported by two previous clinical trials from the USA and Australia. Using a finite mixture model of normal distributions we were able to argue that the dose selection for ADORE is very promising. I will discuss this model and how the information was used for decision making moving forward.